Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamara Darsow

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Diabetes Reports|November 2, 2006
Is the metabolic syndrome a real clinical entity and should it receive drug treatment?Tamara Darsow, David Kendall, David Maggs
Vascular Health and Risk Management|March 1, 2007
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetesJohn Pullman, Tamara Darsow, Juan P Frias
Journal of Diabetes|June 29, 2011
Incretin-based therapiesAnthony H Stonehouse, Tamara Darsow, David G Maggs
Diabetes|May 24, 2012
The American Diabetes Association diabetes research perspectiveVivian A Fonseca, M Sue Kirkman, Tamara Darsow, et al.
Diabetes Care|May 24, 2012
The American Diabetes Association diabetes research perspectiveVivian A Fonseca, M Sue Kirkman, Tamara Darsow, et al.
Diabetes Care|February 22, 2018
American Diabetes Association's Standards of Care: A Paradigm Shift in the Dissemination of InformationWilliam T Cefalu, Erika Gebel Berg, Matthew P Petersen, et al.
The Journal of Biological Chemistry|March 3, 2005
Exocytic trafficking is required for nicotine-induced up-regulation of alpha 4 beta 2 nicotinic acetylcholine receptorsTamara Darsow, T K Booker, Juan Carlos Piña-Crespo, et al.
Diabetes|June 25, 2015
Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research SymposiumRudolph L Leibel, Randy J Seeley, Tamara Darsow, et al.
Diabetes/Metabolism Research and Reviews|August 19, 2007
Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetesAntonio Ceriello, Cameron W Lush, Tamara Darsow, et al.
Diabetes Technology & Therapeutics|April 12, 2007
Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weightDiane Karl, Athena Philis-Tsimikas, Tamara Darsow, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Diabetes Reports|November 2, 2006
Is the metabolic syndrome a real clinical entity and should it receive drug treatment?Tamara Darsow, David Kendall, David Maggs
Vascular Health and Risk Management|March 1, 2007
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetesJohn Pullman, Tamara Darsow, Juan P Frias
Journal of Diabetes|June 29, 2011
Incretin-based therapiesAnthony H Stonehouse, Tamara Darsow, David G Maggs
Diabetes|May 24, 2012
The American Diabetes Association diabetes research perspectiveVivian A Fonseca, M Sue Kirkman, Tamara Darsow, et al.
Diabetes Care|May 24, 2012
The American Diabetes Association diabetes research perspectiveVivian A Fonseca, M Sue Kirkman, Tamara Darsow, et al.
Diabetes Care|February 22, 2018
American Diabetes Association's Standards of Care: A Paradigm Shift in the Dissemination of InformationWilliam T Cefalu, Erika Gebel Berg, Matthew P Petersen, et al.
The Journal of Biological Chemistry|March 3, 2005
Exocytic trafficking is required for nicotine-induced up-regulation of alpha 4 beta 2 nicotinic acetylcholine receptorsTamara Darsow, T K Booker, Juan Carlos Piña-Crespo, et al.
Diabetes|June 25, 2015
Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research SymposiumRudolph L Leibel, Randy J Seeley, Tamara Darsow, et al.
Diabetes/Metabolism Research and Reviews|August 19, 2007
Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetesAntonio Ceriello, Cameron W Lush, Tamara Darsow, et al.
Diabetes Technology & Therapeutics|April 12, 2007
Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weightDiane Karl, Athena Philis-Tsimikas, Tamara Darsow, et al.
Pageof 2